Answers are grounded in this paper and cite their sources.
To report safety and efficacy at Week (W) 48 in the open-label extension (OLE) of the phase 2 trial (NCT04879628) of frexalimab in participants with relapsing multiple sclerosis (RMS).
No takes yet. Share an insight, caveat, or question.
Giovannoni et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: